Antibiotics enters into the industrial-chain competing era
By: tracy ma
Submitted: 2012-02-17 01:15:43 | Word Count: 476
The experts expressed considerable confidence in the antibiotics market. Antibiotics in the drug market are more like the main meal rather than snacks. With the terminal rigid demand, it is no doubt for it to get steadily market growth.
Systemic anti-infectives is the maximum amount of medication in the Chinese medical market a class of such drugs, including antibiotics, antivirals, antifungals, immune serum and immunoglobulin, anti-mycobacterial disease drugs and vaccines. Antibiotics is one of the market is the largest part of the proportion of about 90%.
However, in making antibiotics will continue to grow "to judge the same time, the experts also believe that antibiotics, growth will be lower than the level of development of the overall pharmaceutical market. Global anti-infectives chia seed industry is more mature in the depletion of the listing of new drugs and lower prices and other reasons under the influence of growth is slowing, the five-year average growth rate of about 15%. The same time, the global bacterial drug market is saturated, anti-fungal, antiviral drugs has become the main engine of growth. In China, anti-infective drugs has always occupied a leading hospital market share is shrinking.
A market official said that from 2004 to the present, the market has an oversupply of amoxicillin, however, in recent years related companies continued expansion. Particularly in the amoxicillin into the essential drug list, sales prices fell, while the implementation of electronic monitoring code will allow the cost of production of these products increased.
[ advertisement ]
Increase in market capacity, increased production of raw materials, the price reduction of terminal preparations under the influence of many factors, not very optimistic about the prospects of these antibiotics into the essential drug list; the same time, with some introduction of the policy, the past, some can be used as corporate characteristics of species the class has lost its special status, such as cefuroxime.
The enterprise which have has a complete industrial chain, industrial chain covering a relatively high degree will have a greater risk of resilience, as well as the right to speak on the market. Lower the extent of coverage of the industry chain is much weaker to resist risks. In fact, many pharmaceutical raw materials antibiotic companies are aware of this, have the integration of industrial chain, to improve its coverage of the industry chain.
For the antibiotics enterprises in Chinese domestic market, the first step is to select some verities with large market and good prospects. It can only be regarded as the primary solution and most of companies can do that. If companies can a considerable technical advantage in some certain species, it will become the second step. The enterprises which really have the advantage of the industry chain can stand on high ground, especially in some conventional varieties with large markets and output. Source:http://www.cospcn.com
